| Business Summary | | Aastrom
Biosciences,
Inc.
is
developing
proprietary
process
technologies
and
devices
intended
for
a
broad
range
of
cell
therapy
applications.
The
AastromReplicell
System
is
the
Company's
lead
product
under
development,
and
consists
of
a
clinical
cell
culture
system
that
operates
single-use
therapy
kits
tailored
for
patient
therapy
in
the
emerging
cell
therapy
market.
Aastrom
is
currently
developing
its
own
SC-I
Therapy
Kit,
CB-I
Therapy
Kit
and
CB-II
Therapy
Kit
for
use
in
stem
cell
therapy
in
cancer
patients.
Stem
cell
therapy
is
a
form
of
cell
therapy
used
to
restore
blood
and
immune
system
function
to
cancer
patients
following
chemotherapy
or
radiation
therapy. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ASTM
is
developing
automated
clinical
systems
designed
to
enable
therapeutic
procedures
using
living
cells
in
the
treatment
of
cancer
and
other
diseases
and
in
the
restoration
of
normal
tissues.
For
the
fiscal
year
ended
6/30/01,
revenues
fell
22%
to
$899
thousand.
Net
loss
applicable
to
Common
fell
38%
to
$5.9
million.
Revenues
reflect
lower
product
sales
and
rentals
and
grant
revenues.
Lower
loss
reflects
lower
R&D
costs
for
the
AastromReplicell
System
and
cost
reduction
measures. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| R. Douglas Armstrong, Ph.D., 47 Chairman,
Pres, CEO | $496K | -- | Brian Hampson, 43 VP,
Product Devel. | 160K | $32K | Bruce Husel, 42 VP
Quality Systems and Regulatory Affairs | 154K | 184K | Audrey Hutter VP,
Market Operations | -- | -- | Dollar
amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|